A phase I/II trial enrolled HER−relapsed breast cancer subjects who had already received CDK4/6is (87%), fulvestrant (71%), or chemotherapy (54%), with 58% of them carrying ESR1 mutations. Here, ESR1 is linked to breast carcinoma.